MedTrace Logo

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

NCT00333138 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2017-09-15

Study results available
· View outcomes & findings →

Summary

This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.

Conditions

Interventions

DRUG

FTY720

FTY720 capsule was taken orally once a day

DRUG

Placebo

Placebo 1.25 mg capsule was given once daily

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Canada
  • Denmark
  • Finland
  • France
  • Germany
  • Italy
  • Poland
  • Portugal
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00333138 on ClinicalTrials.gov